At Sandoz, we discover new ways to improve and extend people’s lives. We pioneer novel approaches to help people around the world access high-quality medicine. In 2017, we estimate our products reached more than 500 million patients and our aspiration is to reach 1 billion people.1
Whether the cause be an aging population, changing lifestyle patterns or poor economic outlook, healthcare systems around the world are struggling to cope with the reality of increasing cost containment pressures. But this challenge is not without a solution: generic pharmaceuticals provide significant savings for patients and healthcare systems alike. Generics free up resources for the funding of costlier novel therapies, benefiting patients and incentivizing investment in new, innovative medicines that target unmet medical needs. Sandoz plays an important role in the healthcare system.
In addition to the global #1 ranking in biosimilars2 and generic antibiotics3, dermatology3 and transplantation medicines3, Sandoz portfolio of products in Canada includes two biosimilars and over 700 generic products4 covering 280 molecules and medicinal ingredients spanning multiple therapeutic areas including:
Central nervous system (CNS)
Our broad portfolio encompasses a range of formulations and devices, including injectables, multiple-unit tablets, capsules, creams and gels, transdermal patches, and lyophilized products.
Our medicines are sold in pharmacies and used in hospitals. In 2019, Sandoz was the main provider of generic injectable medications5 to Canadian hospitals.
We are proud to play an essential role in the Canadian health care system. In 2019, Sandoz products were prescribed over 65 million times6 in Canada.
A trusted partner of healthcare professionals, Sandoz Canada has a network of suppliers that stand out for their reliability and high-quality standards. Our dedicated sales force is distinguished by the strong business relationships it has with customers and the excellent service it provides. Our broad product line falls into two categories: Generic medicines and Biosimilars.
1Internal estimate, calculated with the methodology from the Novasrtis group.
2In the combined regions of North America, Europe, Japan and Australia.
5 Internally extrapolated market share (33%) based on IMS data (total injectable sales in hospitals by manufacturer) as of February 2019 for the last 12 months.
6 Overview of Canadian Generic Prescription Drug Market, CGPA, as of September 2019 MAT.
A proven track record across the globe:
We have strong scientific roots that have driven many medical innovations, from the first oral penicillin in 1951 to the first biosimilars in Europe and the US; new delivery technologies (e.g. our award-winning Forspiro inhaler or our Fentanyl patch technology) offer genuine improvements over alternative market offerings. We go beyond providing standard products and add value to the healthcare system through a range of support services and value-added medicines including combination formulations. Examples include the “Sandoz Pro” healthcare professionals app pioneered by Sandoz Canada and the “three-in-one” cardiovascular “polypill” launched by Sandoz Germany in 2015.
Increasing access to medicine is the basis of our day-to-day business model, but we also run a range of targeted corporate responsibility programs to ensure access for those most in need. These programs aim to address specific health needs in underprivileged communities, promote access to medical information and help build capacity.